Saturday 17 October 2026
Export LMRI’s income statement to Excel — free account
Lumexa Imaging Holdings, Inc.
LMRI Healthcare Medical Devices
Lumexa Imaging Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.82% from fiscal 2024. In the quarter to June 2026, revenue grew 7.82%, EPS grew 127.1% and free cash flow grew 257.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.64
0.14
−1.30%
Follow LMRI
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
0.96 | — | — |
Altman Z″-Score (non-manufacturers) |
(0.09) | (0.81) | — |
P/FCF ratio |
0.00 | 128.20 | 128.20 |
P/Operating CF |
76.91 | 621.15 | 621.15 |
Beneish M-Score |
(2.67) | — | — |
P/B ratio |
2.24 | 7.97 | 7.97 |
Price to Tangible BV |
0.00 | 7.97 | 7.97 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
46.17 | 37.36 | 37.36 |
EV/FCF |
(293.46) | 246.79 | 246.79 |
Quick Ratio |
1.17 | 0.93 | — |
Current Ratio |
1.27 | 0.99 | — |
Net Debt/EBITDA |
5.06 | 10.05 | 0.00 |
Debt/Assets |
49.04% | 72.86% | 0.00% |
Debt/Equity |
1.48 | 7.53 | 0.00 |
Asset Turnover |
0.60 | 1.14 | 0.00 |
Operating CF/Net income |
(0.36) | (0.43) | (0.31) |
Capex/Depreciation |
(0.34) | (0.43) | (0.25) |
Interest Coverage |
0.83 | 0.41 | 0.16 |
| (12.60%) | 0.00% | 0.00% | |
| (2.74%) | (11.27%) | 0.00% | |
ROIC |
4.39% | 2.55% | 0.00% |
Return on Tangible Assets |
(24.43%) | (78.42%) | 0.00% |
Average Days of Receivables |
53.82 | 52.31 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
8.84% | 7.42% | 5.89% |
Intangible Assets out of Total Assets |
0.48 | 0.51 | 0.00 |
Share Based Compensation of Revenue |
4.07% | 5.97% | 5.91% |
Graham Net Nets |
(0.72) | (1.04) | (1.04) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(9.94%) | (9.94%) | (9.94%) |
Free Cash Flow Yield |
(0.55%) | 0.78% | 0.78% |
Revenue per Share |
14.41 | 13.66 | 13.48 |
Operating CF per Share |
0.24 | 0.59 | 0.54 |
Capex per Share |
(0.29) | (0.39) | (0.35) |
Free Cash Flow per Share |
(0.05) | 0.19 | 0.19 |
Cash per Share |
0.83 | 0.38 | 0.00 |
Shareholders Equity per Share |
8.26 | 2.33 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
8.26 | 2.33 | 0.00 |
Free Cash Flow |
(3.76) | 13.32 | 13.51 |
Working Capital |
48.07 | (1.14) | — |
Capital Expenditures |
(20.83) | (27.41) | (24.01) |
Net Current Asset Value |
(951.17) | (1,336.39) | 0.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.03 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.43 | 0.52 | 0.00 |
Cash ROIC |
(0.25%) | 0.95% | 0.00% |
Accounts Receivable Turnover |
7.13 | 0.00 | 0.00 |
Accounts Payable Turnover |
23.16 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 |
Average Days of Payables |
18.92 | 12.80 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 |
Average Receivables |
143.42 | — | — |
Average Payables |
37.37 | — | — |
Average Assets |
1,717.56 | 835.28 | — |
Average Common Equity |
373.89 | — | — |
Columns are period end dates